RXi, UMMS Receive Massachusetts Life Sciences Center Funding for ALS Work
April 28, 2011
RXi, UMMS Receive Massachusetts Life Sciences Center Funding for ALS Work
The funding is worth $250,000 per year for two years and will be matched dollar for dollar by RXi. The award is still subject to a formal agreement between RXi and UMMS.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- RXi Inks Ocular Disease Collaboration with UMMS
January 14, 2010 / Gene Silencing News - UMMS, RXi Researcher Wins $5M NIH Grant to Develop Oral RNAi Delivery Tech
October 1, 2009 / Gene Silencing News - RXi Takes License to Self-Delivering RNAi Agents, Ends RNAi Tech-License Deals with UMMS
July 30, 2009 / Gene Silencing News - People in the News: Paul Dorman, Curtis Lockshin
April 25, 2013 / Gene Silencing News - Following Private Placement, RXi Has Funds to Last into 2015
April 4, 2013 / Gene Silencing News